About Summit Therapeutics Inc.
Summit Therapeutics develops ivonescimab, a bispecific antibody targeting lung cancer. No dividend, high beta, binary Phase 3 catalysts and FDA decision risk. Rich CSP premiums but trial readouts create extreme gap potential. Size positions conservatively and respect event dates.
Biotechnology